Research progress on pharmacological effects and mechanisms of cycloastragenol-ZENTIME PUBLISHING CORPORATION LIMITED

Home Perioperative Precision Medicine All issues Issue 4

Research progress on pharmacological effects and mechanisms of cycloastragenol

Weiqi Lin^1,^2,3*, Qin Zhang^1,3* , Sixu Chen^2,4*, Xinyi Xie^3,5 , Jiayin Wang^3,5, Yutong Sun^1,3, Qixiang Xu^3,⁵, Cuifeng Zhang^2,3,4

¹School of Clinical Medicine, Wannan Medical College, Wuhu 241002, Anhui, China. ²Anesthesia Laboratory and Training Center, Wannan Medical College, Wuhu 241002, Anhui, China. ³Wuhu Perioperative Monitoring and Prognostic Technology Research and Development Center, Wannan Medical College, Wuhu 241002, Anhui, China. ⁴School of Anesthesiology, Wannan Medical College, Wuhu 241002, Anhui, China. ⁵School of Pharmacology, Wannan Medical College, Wuhu 241002, Anhui, China.

^*The authors contribute equally.

Address correspondence to: Qixiang Xu, School of Pharmacology, Wannan Medical College, No.22 Wenchang West Road, Yijiang District, Wuhu 241002, Anhui Province, China. Tel: +86-18355305112. E-mail: xuqixiang@wnmc.edu.cn. Cuifeng Zhang, School of Anesthesiology, Wannan Medical College, No.22 Wenchang West Road, Yijiang District, Wuhu 241002, Anhui Province, China. Tel: +86-15551257181. E-mail: zhangcuifeng@wnmc.edu.cn.

Acknowledgement: This work was supported by the Natural Science Foundation Of The Higher Education Insti tutions Of Anhui Province (2024AH051958), the Foundation Of Wannan Medical College (WK2023ZQNZ08), the National University Innovation And Entrepreneurship Training Program (202310368014, 202310368049, 202410368014), the Anhui Province University Innovation And Entrepreneurship Training Program (S202310368087, S202410368004, S202410368009), the Wannan Medical College Undergraduate Research Fund Project (WK2024XS01).

DOI: https://doi.org/10.61189/313450skrqzv

Received January 21, 2025; Accepted April 24, 2025; Published December 31, 2025

Highlights

● Cycloastragenol exhibits anti-aging, anti-cancer, and anti-fibrosis effects.

● Although cycloastragenol shows innovative therapeutic potential, further clinical trials are essential to confirm its clinical applicability.

● Cycloastragenol offers innovative therapeutic avenues for enhancing surgical recovery.

Abstract

Cycloastragenol, a key bioactive compound extracted from Astragalus membranaceus, has attracted increasing attention for its therapeutic potential in anti-aging, cancer treatment, and fibrosis prevention. This review summarizes the pharmacological activities of Cycloastragenol at molecular, cellular, and systemic levels, and discusses its efficacy across various disease models and potential perioperative applications. Current evidence demonstrates that Cycloastragenol exerts dose-dependent therapeutic efficacy through specific molecular targets. However, its clinical translation remains limited, particularly in surgical recovery contexts, underscoring the need for further validation through well-designed clinical trials focused on perioperative outcomes.

Keywords: Cycloastragenol, pharmacological effect, mechanisms of action, research progress

Download

Cite

Views

203

Downloads

Lastest Issue

Main types, application conditions, and standards of thoracic drainage tubes in peacetime and wartime: An expert consensus Multi-objective teaching improves learning results: A randomized controlled trial Research progress on mitochondrial autophagy in sepsis-related acute lung injury A novel multi-functional introducer - Safe Easy Endotracheal kit-flexible Abdominal Drainage in Peacetime and Wartime: An Expert Consensus Optimal placement of gastrointestinal decompresion catheter in patients with gastric cancer: A randomized and controlled clinical study Impact of intestinal immunologic barrier dysfunction on perioperative complications A novel nasopharyngeal airway set-Nasal Pharyngeal Set-flexible Rescue of rocuronium-induced refractory anaphylax is with sugammadex in a laparoscopic hysterecto my: A case report Bibliometric analysis of traditional Chinese medicine in the prevention and treatment of Alzheimer's disease (2015-2024)